nutch_noindex
CANCEL
COVID-2019 Alert

The latest information about the 2019 Novel Coronavirus, including vaccine clinics for children ages 5 years old and older.

La información más reciente sobre el nuevo Coronavirus de 2019, incluidas las clínicas de vacunación para niños de 5 años en adelante.

/nutch_noindex

Ragini Adams, MD

  • Ragini Malika Adams
  • “The patients and their families are the reason that I love coming to work every day.”

I approach patient care with a holistic mindset because many of the patients I take care of have chronic medical conditions and will be with me for a long time. So, it is important for me to ensure that my patients are both healthy and also thriving in their life outside of the clinic or hospital. My goal is that the children who are entrusted to me go on to live full and rich lives because of the foundations we lay together.

The most memorable moment of my career was when my first leukemia patient finished maintenance therapy. After seeing a patient regularly for three years while they receive chemotherapy, I feel like I become part of the family. Every success and every setback that the family feels, I feel too. So, to see a patient finish therapy and know that they have a full and rich life ahead of them is something I will never forget. That feeling is the same with every patient and becomes no less amazing over time.

The patients and their families are the reason that I love coming to work every day. I will always offer you my guidance, but I also make sure you are aware of all of your options. Together, we will come to a shared decision about what we all think is best for yourself or your child and the whole family.

Specialties

Oncology

Hematology-Oncology

Work and Education

Professional Education

East Tennessee State University Medicine, Johnson City, TN, 05/08/2015

Residency

MedStar Georgetown University Pediatrics Program, Washington, DC, 06/30/2018

Fellowship

Stanford University Pediatric Hematology Oncology Fellowship, Palo Alto, CA, 07/06/2021

Board Certifications

Pediatrics, American Board of Pediatrics

Conditions Treated

Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Pediatric Leukemia

Pediatric Lymphoma

All Publications

Evans Syndrome Shyam, R., Sakamoto, K. Medscape. 2020

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), yet 40-50% of patients will eventually succumb to their disease demonstrating a pressing need for novel therapeutic options. Gene expression profiling has identified messenger RNA's that lead to transformation, but critical events transforming cells are normally executed by kinases. Therefore, we hypothesized that previously unrecognized kinases may contribute to DLBCL pathogenesis. We performed the first comprehensive analysis of global kinase activity in DLBCL, to identify novel therapeutic targets, and discovered that Germinal Center Kinase (GCK) was extensively activated. GCK RNA interference and small molecule inhibition induced cell cycle arrest and apoptosis in DLBCL cell lines and primary tumors in vitro and decreased the tumor growth rate in vivo, resulting in a significantly extended lifespan of mice bearing DLBCL xenografts. GCK expression was also linked to adverse clinical outcome in a cohort of 151 primary DLBCL patients. These studies demonstrate, for the first time, that GCK is a molecular therapeutic target in DLBCL tumors and that inhibiting GCK may significantly extend DLBCL patient survival. Since the majority of DLBCL tumors (~80%) exhibit activation of GCK, this therapy may be applicable to most patients.

View details for DOI 10.1182/blood-2016-02-696856

View details for PubMedID 27151888

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., Gentles, A. J., Martinez, E., Zhu, D., Chapman, J. R., Cortizas, E., Shyam, R., Chinichian, S., Advani, R., Tan, L., Zhang, J., Choi, H. G., Tibshirani, R., Buhrlage, S. J., Gratzinger, D., Verdun, R., Gray, N. S., Lossos, I. S. 2016; 128 (2): 239-248
The effect of iron- and light-limitation on phytoplankton communities of deep chlorophyll maxima of the western Pacific Ocean JOURNAL OF MARINE RESEARCH Johnson, Z. I., Shyam, R., Ritchie, A. E., Mioni, C., Lance, V. P., Murray, J. W., Zinser, E. R. 2010; 68 (2): 283308

Abstract

Diffuse large B cell lymphoma (DLBCL) is clinically and biologically heterogeneous. In most cases of DLBCL, lymphoma cells co-express vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2, suggesting autocrine in addition to angiogenic effects. We enumerated microvessel density and scored lymphoma cell expression of VEGF, VEGFR1, VEGFR2 and phosphorylated VEGFR2 in 162 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone)-like regimens. VEGFR2 expression correlated with shorter overall survival (OS) independent of International Prognostic Index (IPI) (P = 0.0028). Phosphorylated VEGFR2 (detected in 13% of cases) correlated with shorter progression-free survival (PFS, P = 0.044) and trended toward shorter OS on univariate analysis. VEGFR1 was not predictive of survival on univariate analysis, but it did correlate with better OS on multivariate analysis with VEGF, VEGFR2 and IPI (P = 0.036); in patients with weak VEGFR2, lack of VEGFR1 coexpression was significantly correlated with poor OS independent of IPI (P = 0.01). These results are concordant with our prior finding of an association of VEGFR1 with longer OS in DLBCL treated with chemotherapy alone. We postulate that VEGFR1 may oppose autocrine VEGFR2 signalling in DLBCL by competing for VEGF binding. In contrast to our prior results with chemotherapy alone, microvessel density was not prognostic of PFS or OS with R-CHOP-like therapy.

View details for DOI 10.1111/j.1365-2141.2009.07942.x

View details for PubMedID 19821819

Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP) BRITISH JOURNAL OF HAEMATOLOGY Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., Horning, S., Sehn, L. H., Farinha, P., Briones, J., Lossos, I. S., Gascoyne, R. D., Natkunam, Y. 2010; 148 (2): 235-244